ARCT News and Press, Arcturus Therapeutics Ltd. From 07/29/20

The collective effort of pharmaceutical companies to develop a safe and effective coronavirus vaccine is often referred to as a "race", but it's not clear investors understand what the race is against. The "race" doesn't pit one company against another, as the typical first-to-market advantage d...

Arcturus Therapeutics (NASDAQ: ARCT ) has priced it previously announced public offering of ~3.3M shares at $53/share, for gross proceeds of ~$173M. More news on: Arcturus Therapeutics Holdings Inc., Healthcare stocks news, , Read more ...

SAN DIEGO, July 29, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and res...

Biotech Pulse Biotechs continue to be one of the leading healthcare groups and along with diagnostics represent two of the best segments of healthcare. The first half saw biotechs recover quicker from the March selloff than most of the market, and reach a milestone that took 5 years to achie...

Israel secures rights to stockpile and reserve doses of LUNAR-COV19 for its citizens Israel is the second country to reserve supply of LUNAR-COV19 SAN DIEGO, July 23, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus&#x...

Singapore's Health Sciences Authority has signed off on Phase 1/2 clinical trial evaluating Arcturus Therapeutics Holdings (NASDAQ: ARCT ) and Duke-NUs Medical School's mRNA-based COVID-19 vaccine candidate LUNAR-COV19 in up to 108 healthy adult volunteers. More news on: Arcturus Thera...

Human dosing of LUNAR-COV19 expected soon Differentiated STARR™ mRNA vaccine expected to produce humoral and cellular immunity at very low doses New preclinical data demonstrates neutralizing antibody titers continue to increase for 50 days after a single administration ...

Investors are apparently reacting to Pfizer and BioNTech's release of encouraging preliminary early-stage data on COVID-19 vaccine candidate BNT162b1 that showed significant jumps in neutralizing antibodies compared to convalescent plasma. More news on: AstraZeneca PLC, GlaxoSmithKline p...

Renowned experts in virology, infectious disease, vaccine development and public health to support Arcturus’ COVID-19 vaccine program, LUNAR-COV19 Company remains on track to begin clinical trial for COVID-19 vaccine this summer SAN DIEGO, July 01, 2020 (GLOBE NEWSWIRE) -- A...

The FDA has released guidance on its standards for approving a COVID-19 vaccine, including a requirement that it must demonstrate that it is at least 50% more effective than placebo (a low bar compared to vaccines for other infectious diseases). More news on: AstraZeneca PLC, GlaxoSmithK...